JP Morgan Chase
CHRS icon

JP Morgan Chase’s Coherus Oncology CHRS Stock Holding History

JP Morgan Chase’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,600
Closed -$117K – 5782
2019
Q1 		$117K Buy
+8,600
New +$115K ﹤0.01% 4832
2018
Q4 		– Sell
-35,200
Closed -$581K – 5706
2018
Q3 		$581K Buy
+35,200
New +$624K ﹤0.01% 4212
2018
Q1 		– Sell
-22,500
Closed -$198K – 5402
2017
Q4 		$198K Hold
22,500
– – ﹤0.01% 4417
2017
Q3 		$304K Sell
22,500
-2,500
-10% -$33.1K ﹤0.01% 3981
2017
Q2 		$359K Hold
25,000
– – ﹤0.01% 3840
2017
Q1 		$529K Buy
+25,000
New +$615K ﹤0.01% 3684

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

JP Morgan Chase's CHRS Position: Q2 2026 in Review

JP Morgan Chase increased its Coherus Oncology (CHRS) stake by 24% in Q2 2026, buying an estimated $21.1K and bringing the position to 66,066 shares worth $95.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6090.

JP Morgan Chase first reported a position in CHRS in Q4 2014 and has held it in 47 quarters since. The position peaked at $115M in Q3 2021. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • JP Morgan Chase held 66,066 shares of Coherus Oncology worth $95.8K as of Q2 2026.
  • JP Morgan Chase bought 12,910 Coherus Oncology shares in Q2 2026, an estimated $21.1K.
  • Coherus Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6090 holding.
  • JP Morgan Chase first reported a position in Coherus Oncology in Q4 2014 and has held it in 47 quarters since.
  • JP Morgan Chase's Coherus Oncology position peaked at $115M in Q3 2021.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.